Jan Baughman
About
Jan Baughman is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology.
According to data from OpenAlex, Jan Baughman has authored 25 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Immunology. Recurrent topics in Jan Baughman's work include Monoclonal and Polyclonal Antibodies Research (13 papers), CAR-T cell therapy research (8 papers) and HER2/EGFR in Cancer Research (6 papers). Jan Baughman is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), CAR-T cell therapy research (8 papers) and HER2/EGFR in Cancer Research (6 papers). Jan Baughman collaborates with scholars based in United States, South Korea and United Kingdom. Jan Baughman's co-authors include Paul A. Moore, Howard A. Burris, Todd M. Bauer, Giuseppe Giaccone, Jeffrey L. Nordstrom, Robert J. Lechleider, Gurunadh R. Chichili, Yung‐Jue Bang, Do‐Youn Oh and S.-A. Im and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Jan Baughman
25 papers receiving 431 citations
Peers
Jan Baughman
A. Schoberth Germany
Diane Feingersh United States
Melissa L. Comstock United States
Candy Garcia United States
Johannes Andel Austria
Yunfei Shi China
Cesare Magalotti Italy
E Holz Germany
Ningning Dong China
Guillaume Manson France
Citations per year, relative to Jan Baughman Jan Baughman (= 1×)
peers
A. Schoberth
Countries citing papers authored by Jan Baughman
Since
Specialization
Citations
This map shows the geographic impact of Jan Baughman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Baughman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Baughman more than expected).
Fields of papers citing papers by Jan Baughman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jan Baughman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Baughman. The network helps show where Jan Baughman may publish in the future.
Co-authorship network of co-authors of Jan Baughman
This figure shows the co-authorship network connecting the top 25 collaborators of Jan Baughman. A scholar is included among the top collaborators of Jan Baughman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Baughman. Jan Baughman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rutella, Sergio, John Muth, Jayakumar Vadakekolathu, et al.. (2023). WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML). Blood. 142(Supplement 1). 466–466.
2.
Muth, John F., Alexander Hamil, Paula Comune Pennacchi, et al.. (2023). WU-NK-101, an enhanced memory natural killer (NK) cell therapy, with cetuximab (Ctx) for the treatment of advanced colorectal cancer (CRC).. Journal of Clinical Oncology. 41(4_suppl). 170–170.
3.
Cashen, Amanda F., Hongtao Liu, Monzr M. Al Malki, et al.. (2022). A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. 140(Supplement 1). 12740–12741.
4.
Catenacci, Daniel V.T., Kian‐Huat Lim, Hope E. Uronis, et al.. (2019). Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).. Journal of Clinical Oncology. 37(4_suppl). 65–65.
5.
Im, S-A, Giuseppe Giaccone, Jeffrey L. Nordstrom, et al.. (2019). Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy. Cancer Research. 79(4_Supplement). P6–18.
6.
Wei, Andrew H., Chun Yew Fong, Pau Montesinos, et al.. (2019). A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 134(Supplement_1). 2662–2662.
7.
Rutella, Sergio, Jayakumar Vadakekolathu, Stephen Reeder, et al.. (2019). Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA). Annals of Oncology. 30. v38–v39.
8.
Catenacci, Daniel V.T., Haeseong Park, Hope E. Uronis, et al.. (2018). Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. Journal of Clinical Oncology. 36(15_suppl). 4030–4030.
9.
Catenacci, Daniel V.T., Hope E. Uronis, Yoon‐Koo Kang, et al.. (2018). Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). Annals of Oncology. 29. viii223–viii223.
10.
Rettig, Michael P., John E. Godwin, Norbert Vey, et al.. (2017). Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies. Blood. 130. 1365–1365.
11.
Bang, Yung‐Jue, Giuseppe Giaccone, S.-A. Im, et al.. (2017). First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals of Oncology. 28(4). 855–861.
12.
Rizvi, Naiyer A., Deryk Loo, Jan Baughman, et al.. (2016). A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.. Journal of Clinical Oncology. 34(15_suppl). TPS3104–TPS3104.
13.
Tolcher, Anthony W., Evan Alley, Jan Baughman, et al.. (2016). Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature.. Journal of Clinical Oncology. 34(15_suppl). TPS3105–TPS3105.
14.
Baughman, Jan, Deryk Loo, Francine Chen, et al.. (2015). A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P177–P177.
15.
Urba, Walter J., Bartosz Chmielowski, Deryk Loo, et al.. (2015). A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P176–P176.
16.
Powderly, John D., Gregory M. Coté, Keith T. Flaherty, et al.. (2015). Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). O8–O8.
17.
Burris, Howard A., Giuseppe Giaccone, Seock‐Ah Im, et al.. (2015). Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 523–523.
18.
Uy, Geoffrey L., Stanford J. Stewart, Jan Baughman, et al.. (2014). A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). Journal for ImmunoTherapy of Cancer. 2(Suppl 3). P87–P87.
19.
Burris, Howard A., Lee S. Rosen, Caio Rocha‐Lima, et al.. (2010). Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma. Clinical Cancer Research. 16(5). 1673–1681.
20.
Kavanaugh, Arthur, Mark C. Genovese, Jan Baughman, et al.. (2003). Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial.. PubMed. 30(3). 449–54.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Schoberth Breakdown of academic impact, for papers by Diane Feingersh Breakdown of academic impact, for papers by Melissa L. Comstock Breakdown of academic impact, for papers by Candy Garcia Breakdown of academic impact, for papers by Johannes Andel Breakdown of academic impact, for papers by Yunfei Shi Breakdown of academic impact, for papers by Cesare Magalotti Breakdown of academic impact, for papers by E Holz Breakdown of academic impact, for papers by Ningning Dong Breakdown of academic impact, for papers by Guillaume Manson